LRI Investments’s Altamira Therapeutics Ltd CYTO Stock Holding History

LRI Investments’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	1	–	–	﹤0.01%	2017
2026 Q1	$0	Hold	1	–	–	﹤0.01%	1512
2025 Q4	$0	Hold	1	–	–	﹤0.01%	1422
2025 Q3	$0	Hold	1	–	–	﹤0.01%	1372
2025 Q2	$0	Hold	1	–	–	﹤0.01%	1312
2025 Q1	$0	Hold	1	–	–	﹤0.01%	1263
2024 Q4	$0	Hold	1	–	–	﹤0.01%	1177
2024 Q3	$0	Hold	1	–	–	﹤0.01%	1219
2024 Q2	$1	Hold	1	–	–	﹤0.01%	1134
2024 Q1	$2	Buy	+1	New	+$2	﹤0.01%	840

LRI Investments's CYTO Position: Q2 2026 in Review

LRI Investments held its Altamira Therapeutics Ltd (CYTO) position steady in Q2 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2017.

LRI Investments first reported a position in CYTO in Q1 2024 and has held it in 10 quarters since. The position peaked at $2 in Q1 2024. 1 fund tracked by Wall St. Rank holds CYTO as of Q2 2026.

LRI Investments held 1 share of Altamira Therapeutics Ltd worth $0 as of Q2 2026.
LRI Investments left its Altamira Therapeutics Ltd share count unchanged in Q2 2026.
Altamira Therapeutics Ltd made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #2017 holding.
LRI Investments first reported a position in Altamira Therapeutics Ltd in Q1 2024 and has held it in 10 quarters since.
LRI Investments's Altamira Therapeutics Ltd position peaked at $2 in Q1 2024.
1 fund tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.